Handelsavisen
prelaunch
Companies ›Healthcare ›GOSS.O
GO
GOSS.O — NASDAQ Biotechnology & Life-Science Tools

Gossamer Bio Inc

$0,17
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
40,0M USD
P/E
—
EV / Rev
5,1x
Div yield
—
Op margin
—
ROE
-156,9 %
Net margin
—
Debt / equity
7,72
Beta
—
52w range
—
Volume
78
Day range
—
Prev close
$0,22
Open
$0,23
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Gossamer Bio Inc is a biotechnology company focused on the development of inhaled therapies for the treatment of respiratory diseases, primarily through its proprietary drug delivery platform.

Business. Gossamer Bio Inc (GOSS.O) is a biotechnology company operating within the Healthcare sector, specifically focused on pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As segment and geographic breakdowns are not provided, the company is described at the industry level as an entity engaged in healthcare diagnostics and biotechnology activities.

Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
Generated · model-assisted
Sell-side consensus
HOLD10 analysts
4 buy5 hold1 sell
Avg 12m price target4,35

Analyst recommendations

10 analysts · consensus Hold
Buy4
Hold5
Sell1
12-month price target
4,35
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Hold
10 analysts · indicative
Ownership→
JPMorgan Private Bank (United States)
largest disclosed fund holder
Profitability→
-156,9 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning GOSS.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to GOSS.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Gossamer Bio Inc (GOSS.O) is a biotechnology company operating within the Healthcare sector, specifically focused on pharmaceuticals and medical research. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As segment and geographic breakdowns are not provided, the company is described at the industry level as an entity engaged in healthcare diagnostics and biotechnology activities.

    Classification99 %
    SectorHealth Care
    Industry groupBiotechnology & Life-Science Tools
    AI synthesis
    GENERATED

    Gossamer Bio operates with a high debt-to-equity ratio of 7.72, indicating a capital structure heavily reliant on debt financing. The company's liquidity position is characterized by a current ratio of 7.13, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's free cash flow is negative at -$41.6 million, and its operating cash flow is -$52.3 million, signaling ongoing cash burn.

    Profitability metrics show that Gossamer Bio is currently unprofitable, with a net income of -$41.9 million and an operating income of -$41.9 million. The return on equity is -1.569, and the return on assets is -0.1617, both significantly below the industry median for biotechnology firms. The company's price-to-book ratio of 2.9 suggests that the market is valuing the company at a premium to its book value, despite its negative earnings.

    The company's revenue is not disclosed in the provided data, but its geographic exposure is not specified. Given the nature of biotechnology firms, it is likely that Gossamer Bio has a global reach, particularly in the United States and other developed markets where respiratory diseases are prevalent. However, the lack of segment-specific revenue data limits the ability to assess geographic concentration.

    Looking ahead, the company's growth trajectory is uncertain. Analysts have provided a wide range of price targets, from $0.30 to $15.00, with a mean of $4.35 and a median of $2.00. The mean recommendation is 2.60, indicating a mixed outlook. The company's negative operating and free cash flows suggest that it is not currently generating sufficient cash to fund operations, and it may need to seek additional financing or partnerships to advance its pipeline.

    The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash is negative after subtracting total debt, which could pose challenges in maintaining operations without further capital raising. The dilution risk is low, but the company's high debt load and negative cash flows could necessitate future equity offerings, which would dilute existing shareholders.

    Recent events include the continued development of its inhaled therapies, with a focus on respiratory diseases. The company has not disclosed any recent major partnerships or product approvals, and its financial performance remains a concern for investors. The company's reliance on external financing and the competitive nature of the biotechnology sector add to the uncertainty of its future prospects.

    Key takeaways
    • Gossamer Bio is a biotechnology company with a focus on inhaled therapies for respiratory diseases.
    • The company is currently unprofitable, with significant negative cash flows and a high debt-to-equity ratio.
    • Analysts have provided a wide range of price targets, indicating a mixed outlook for the company.
    • The company's liquidity position is medium risk, and its dilution risk is low.
    • The company's future growth is uncertain, and it may need to seek additional financing to continue operations.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-17
    Q4 2025 · Quarter highlights
    Open report →

    Revenue $13.8M, +47,1% YoY; Operating income −27,4% YoY.

    Revenue$13.8M+47,1 % YoY
    Operating income-$46.0M−27,4 % YoY
    Net income-$47.2M−43,0 % YoY
    Free cash flow-$47.2M−43,5 % YoY
    EPS—
    Operating cash flow-$171.3M−4 838,5 % YoY
    Financials
    Income statement
    Revenue$13.8M
    Gross profit—
    Operating income-$46.0M
    Net income-$47.2M
    Margins
    Gross margin—
    Operating margin-333.6%
    Net margin-342.3%
    FCF margin-342.3%
    Balance sheet
    Total assets$172.2M
    Total liabilities$295.0M
    Total equity-$122.8M
    Cash & equivalents$37.7M
    Long-term debt$198.5M
    Cash flow
    Operating cash flow-$171.3M
    CapEx-$79.0k
    Free cash flow-$47.2M
    SBC—
    P&L flow · revenue → net income
    Revenue $13.8MOperating costs $59.8MTax $1.2MNet income $47.2M
    Highlights
    • ▍Revenue $13.8M, +47,1% YoY
    • ▍Operating income −27,4% YoY
    • ▍Net income −43,0% YoY
    • ▍Free cash flow −43,5% YoY
    • ▍Net margin -342.3%

    Valuation TTM

    Market price
    $0,17
    Market cap
    $77.4M
    Enterprise valueⓘ
    $245.0M
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    5.1x
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    2.9x
    P / Tangible bookⓘ
    2.9x
    Tangible book
    $26.7M
    Net cashⓘ
    -$167.5M
    Current ratioⓘ
    7.1
    Debt / equityⓘ
    7.7
    ROAⓘ
    -16.2%
    ROEⓘ
    -1.6%
    Cash conversionⓘ
    125.0%
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryBiotechnology & Life-Science Tools27,7B node revenueIQV 58,8%CRL 14,5%MEDP 9,1%ALKS 5,3%PIII 5,3%ORGO 2,0%NAGE 0,5%SPRY 0,3%Other 4,2%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)GOSS 0,2% · rank #17 of 78

    Business relationships

    Business relationships3 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries3
    EX21:501c32866187EX21:501c32866187Subsidiarie97%
    EX21:d0f01c789a4cEX21:d0f01c789a4cSubsidiarie97%
    EX21:f6b01628a497EX21:f6b01628a497Subsidiarie97%

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs GOSS · multiples and returns
    IQ
    IQV—
    Iqvia Holdings Inc
    $181,94
    30,9B USD
    P/E
    22,7x
    — vs self
    Div yield
    —
    — vs self
    ROE
    21,9 %
    +178,8 vs self
    CR
    CRL—
    Charles River Laboratories
    $230,87
    11,4B USD
    P/E
    —
    — vs self
    Div yield
    —
    — vs self
    ROE
    -4,6 %
    +152,3 vs self
    ME
    MEDP—
    Medpace Holdings Inc
    $576,00
    16,7B USD
    P/E
    34,4x
    — vs self
    Div yield
    —
    — vs self
    ROE
    75,4 %
    +232,3 vs self
    AL
    ALKS—
    Alkermes PLC
    $49,53
    8,2B USD
    P/E
    39,8x
    — vs self
    Div yield
    —
    — vs self
    ROE
    8,4 %
    +165,3 vs self
    PI
    PIII—
    P3 Health Partners Inc
    $10,20
    73,8M USD
    P/E
    —
    — vs self
    Div yield
    —
    — vs self
    ROE
    95,3 %
    +252,2 vs self
    OR
    ORGO—
    Organogenesis Holdings Inc
    $2,38
    306,2M USD
    P/E
    9,0x
    — vs self
    Div yield
    —
    — vs self
    ROE
    8,5 %
    +165,4 vs self
    NA
    NAGE—
    Niagen Bioscience Inc
    $3,53
    281,1M USD
    P/E
    17,4x
    — vs self
    Div yield
    —
    — vs self
    ROE
    22,7 %
    +179,6 vs self
    SP
    SPRY—
    Ars Pharmaceuticals Inc
    $5,51
    547,1M USD
    P/E
    —
    — vs self
    Div yield
    —
    — vs self
    ROE
    -149,9 %
    +7,0 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,46
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    10
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate-0,46
    Revenue—no estimate—no estimate23,5M USD
    Operating income—no estimate—no estimate-125,9M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution10 analysts
    Strong buy1
    Buy3
    Hold5
    Sell1
    Strong sell0
    12-month price target$4,35 · Median $2,00
    Low $0,30High $15,00
    Operating income · consensus-125,9M USD
    EPS surprise
    −61,9 %
    reported vs consensus · miss
    Revenue surprise
    +106,3 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$0,30
    Mean$4,35
    Median$2,00
    High$15,00
    Spot$0,17
    +2451.3 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    ROE-156,9 %Bottom quartile
    D/E7,72Bottom quartile
    Cash Conv1,25Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 5 201 250 sh64 grants12 insiders
    • Daniel Thomas ODirector · Stock Option (Right to Buy) → Common StockAcquired 115 000 @ $0,18grant · 2026-06-04
    • Cox Russell J.Director · Stock Option (Right to Buy) → Common StockAcquired 115 000 @ $0,18grant · 2026-06-04
    • Milligan SandraDirector · Stock Option (Right to Buy) → Common StockAcquired 115 000 @ $0,18grant · 2026-06-04
    • Nathan Steven DDirector · Stock Option (Right to Buy) → Common StockAcquired 115 000 @ $0,18grant · 2026-06-04
    • Quisel John DDirector · Stock Option (Right to Buy) → Common StockAcquired 115 000 @ $0,18grant · 2026-06-04
    • Drynan SkyeDirector · Stock Option (Right to Buy) → Common StockAcquired 115 000 @ $0,18grant · 2026-06-04
    • Aranda RichardChief Medical Officer · Stock Option (Right to Buy) → Common StockDisposed 40 000 @ $1,36disposition · 2026-03-19
    • Christian WaageEVP, Tech Ops and Admin · Stock Option (Right to Buy) → Common StockDisposed 47 667 @ $1,36disposition · 2026-03-19
    • Christian WaageEVP, Tech Ops and Admin · Stock Option (Right to Buy) → Common StockDisposed 60 000 @ $1,36disposition · 2026-03-19
    • Christian WaageEVP, Tech Ops and Admin · Stock Option (Right to Buy) → Common StockDisposed 126 667 @ $1,36disposition · 2026-03-19
    • Christian WaageEVP, Tech Ops and Admin · Stock Option (Right to Buy) → Common StockDisposed 157 500 @ $1,21disposition · 2026-03-19
    • Christian WaageEVP, Tech Ops and Admin · Stock Option (Right to Buy) → Common StockDisposed 125 000 @ $0,84disposition · 2026-03-19
    • Christian WaageEVP, Tech Ops and Admin · Stock Option (Right to Buy) → Common StockDisposed 375 000 @ $0,97disposition · 2026-03-19
    • Christian WaageEVP, Tech Ops and Admin · Stock Option (Right to Buy) → Common StockDisposed 440 000 @ $1,13disposition · 2026-03-19
    • Christian WaageEVP, Tech Ops and Admin · Stock Option (Right to Buy) → Common StockDisposed 506 250 @ $2,88disposition · 2026-03-19
    • Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 96 667 @ $0,45grant · 2026-03-19
    • Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 47 667 @ $0,45grant · 2026-03-19
    • Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 60 000 @ $0,45grant · 2026-03-19
    • Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 100 000 @ $0,45grant · 2026-03-19
    • Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 176 667 @ $0,45grant · 2026-03-19
    • Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 211 500 @ $0,45grant · 2026-03-19
    • Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 181 250 @ $0,45grant · 2026-03-19
    • Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 543 750 @ $0,45grant · 2026-03-19
    • Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 638 000 @ $0,45grant · 2026-03-19
    • Giraudo BryanCOO/CFO · Stock Option (Right to Buy) → Common StockAcquired 693 750 @ $0,45grant · 2026-03-19

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • Gossamer Bio Inc Market data — financials · 2026-05-28
    • Gossamer Bio Inc Market data — analyst estimates · 2026-05-28
    • Gossamer Bio Inc Market data — ESG · 2026-05-28

    Ownership & reference

    Top holders

    • JPMorgan Private Bank (United States)Investment Managers · as of 2026-03-310,15 %$2M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$3M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$6M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$40M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$2M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$3M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$1M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$0M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$0M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net buying1 buys · 0 sellsnet $50K7 insiders · last 365d
    • Hasnain FaheemDirector, President & CEO · Common StockOther 280 000 · 2026-01-02
    • Giraudo BryanCOO/CFO · Common StockOther 115 750 · 2026-01-02
    • Smith Robert Paul JRChief Commercial Officer · Common StockOther 93 750 · 2026-01-02
    • Aranda RichardChief Medical Officer · Common StockOther 93 750 · 2026-01-02
    • Peterson CarynEVP, Regulatory Affairs · Common StockOther 84 500 · 2026-01-02
    • Christian WaageEVP, Tech Ops and Admin · Common StockOther 84 500 · 2026-01-02
    • Smith Robert Paul JRChief Commercial Officer · Common StockOther 162 500 · 2025-10-01
    • Christian WaageEVP, Tech Ops and Admin · Common StockOther 125 000 · 2025-10-01
    • Giraudo BryanCOO/CFO · Common StockOther 181 250 · 2025-10-01
    • Aranda RichardChief Medical Officer · Common StockOther 162 500 · 2025-10-01
    • Hasnain FaheemDirector, President & CEO · Common StockOther 437 500 · 2025-10-01
    • Peterson CarynEVP, Regulatory Affairs · Common StockOther 125 000 · 2025-10-01
    • Milligan SandraDirector · Common StockBought 26 050 @ $1,92$50K · 2025-08-19

    Short positioning

    73.2Mshares short+36.3% vs prior
    3.79days to cover
    69.2%short of daily vol
    274.1Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    GOSS.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    GOSSEX21:501EX21:d0fEX21:f6bBiotechnology
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -200.0%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -4,838.5%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): -2.40xDerived (calculated)
    • Current ratio (FY 2025-12-31): 2.64xDerived (calculated)
    • Return on assets (FY 2025-12-31): -98.9%Derived (calculated)
    • Return on equity (FY 2025-12-31): 138.8%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -200.0%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -18.1%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -201.4%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -45.4%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -184.9%Derived (calculated)
    • Net margin (FY 2025-12-31): -351.5%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -516.2%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): -57.7%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 3.2%Derived (calculated)
    • Current liabilities (annual): USD 63.44MSEC XBRL filing
    • Current assets (annual): USD 167.64MSEC XBRL filing
    • Operating cash flow (annual): USD -171.27MSEC XBRL filing
    • Total liabilities (annual): USD 295.01MSEC XBRL filing
    • Shares outstanding (annual): 233.68MSEC XBRL filing
    • Total operating expenses (annual): USD 219.2MSEC XBRL filing
    • Revenue (annual): USD 48.47MSEC XBRL filing
    • Net income (annual): USD -170.37MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-08-04 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-07-29 22:34 UTCEVENTHa Price Listing GOSS remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 105 consecutive trading days (last close $0.14). cure deadline 2027-01-17 (172 days remaining).
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-17FILING8-K filing →
    2026-06-09FILINGDEF 14A filing →
    2026-06-05FILING8-K filing →
    2026-06-05FILING8-K filing →
    2026-06-04 00:00 UTCINSIDER6 insider transactions — 2026-06 6 derivative
    2026-06-04INSIDERMilligan Sandra acquired 115.0k sh Stock Option (Right to Buy) — Director
    2026-06-04INSIDERDaniel Thomas O acquired 115.0k sh Stock Option (Right to Buy) — Director
    2026-06-04INSIDERDrynan Skye acquired 115.0k sh Stock Option (Right to Buy) — Director
    2026-06-04INSIDERQuisel John D acquired 115.0k sh Stock Option (Right to Buy) — Director
    2026-06-04INSIDERNathan Steven D acquired 115.0k sh Stock Option (Right to Buy) — Director
    2026-06-04INSIDERCox Russell J. acquired 115.0k sh Stock Option (Right to Buy) — Director
    2026-06-02FILING8-K filing →
    2026-05-18FILING8-K filing →
    2026-05-15FILING10-Q filing →
    2026-04-24FILINGDEF 14A filing →
    2026-04-09FILING8-K filing →
    2026-03-19 00:00 UTCINSIDER104 insider transactions — 2026-03 104 derivative
    2026-03-19INSIDERAranda Richard disposed of 157.5k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-03-19INSIDERAranda Richard disposed of 562.5k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-03-19INSIDERAranda Richard disposed of 572.0k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-03-19INSIDERAranda Richard disposed of 487.5k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-03-19INSIDERAranda Richard disposed of 162.5k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-03-19INSIDERAranda Richard disposed of 126.7k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-03-19INSIDERAranda Richard disposed of 20.0k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-03-19INSIDERAranda Richard disposed of 40.0k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-03-19INSIDERAranda Richard disposed of 22.8k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-03-19INSIDERAranda Richard disposed of 9.2k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-03-19INSIDERAranda Richard disposed of 30.0k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-03-19INSIDERAranda Richard acquired 562.5k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-03-19INSIDERAranda Richard acquired 572.0k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-03-19INSIDERAranda Richard acquired 487.5k sh Stock Option (Right to Buy) — Chief Medical Officer
    2026-03-19INSIDERHasnain Faheem disposed of 325.0k sh Stock Option (Right to Buy) — Director, President & CEO
    2026-03-19INSIDERHasnain Faheem disposed of 47.0k sh Stock Option (Right to Buy) — Director, President & CEO
    2026-03-19INSIDERHasnain Faheem disposed of 43.5k sh Stock Option (Right to Buy) — Director, President & CEO
    2026-03-19INSIDERHasnain Faheem acquired 1.68M sh Stock Option (Right to Buy) — Director, President & CEO
    2026-03-19INSIDERHasnain Faheem acquired 1.54M sh Stock Option (Right to Buy) — Director, President & CEO
    2026-03-17 16:01 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 13.8M · Net USD -47.2M
    Showing the 40 most recent of 71 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage